• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

上皮/癌抗原EGP-1,可被单克隆抗体RS7-3G11识别,其丝氨酸303位点发生磷酸化。

The epithelial/carcinoma antigen EGP-1, recognized by monoclonal antibody RS7-3G11, is phosphorylated on serine 303.

作者信息

Basu A, Goldenberg D M, Stein R

机构信息

Department of Biochemistry and Molecular Biology, Graduate School of Biomedical Science, University of Medicine and Dentistry of New Jersey, Newark 07103, USA.

出版信息

Int J Cancer. 1995 Aug 9;62(4):472-9. doi: 10.1002/ijc.2910620419.

DOI:10.1002/ijc.2910620419
PMID:7635574
Abstract

RS7-3G11 is a murine monoclonal antibody (MAb) raised against human non-small-cell lung carcinoma, and is under clinical evaluation. The epithelial/carcinoma antigen EGP-1, defined by RS7-3G11, was isolated and purified to homogeneity from a cervical carcinoma cell line, ME180. EGP-1 is a glycoprotein with an average molecular mass of 47.8 kDa. Metabolic labeling of the antigen with 32P-orthophosphate and subsequent immunoprecipitation with RS7-3G11 showed that it is a phosphoprotein. Phosphoamino acid analysis of the in vivo phosphorylated EGP-1 revealed that the phosphorylation is on serine. In vitro analysis with purified antigen demonstrated that protein kinase C, and not protein kinase A, is involved in phosphorylating the antigen in vitro. In vitro analysis indicated a stoichiometry of phosphorylation of 0.54 mole of phosphate per mole of EGP-1. Phosphoamino acid analysis and phosphopeptide mapping of the antigen phosphorylated in vitro by protein kinase C showed that phosphorylation occurred on a serine residue, specifically on serine 303, located in the cytoplasmic domain of EGP-1. Treatment of ME180 cells with phorbol ester increased the phosphorylation of EGP-1. The biological function of EGP-1 remains to be elucidated. In this report we elucidate an involvement of protein kinase C in phosphorylating EGP-1, which may signify a role for this antigen in signal transduction across the cell membrane.

摘要

RS7-3G11是一种针对人非小细胞肺癌产生的鼠单克隆抗体(MAb),目前正处于临床评估阶段。由RS7-3G11定义的上皮/癌抗原EGP-1从宫颈癌细胞系ME180中分离并纯化至同质。EGP-1是一种平均分子量为47.8 kDa的糖蛋白。用32P-正磷酸盐对该抗原进行代谢标记,随后用RS7-3G11进行免疫沉淀,结果表明它是一种磷蛋白。对体内磷酸化的EGP-1进行磷酸氨基酸分析表明,磷酸化发生在丝氨酸上。用纯化抗原进行的体外分析表明,参与体外磷酸化该抗原的是蛋白激酶C,而非蛋白激酶A。体外分析表明,EGP-1的磷酸化化学计量比为每摩尔0.54摩尔磷酸盐。对蛋白激酶C体外磷酸化的抗原进行磷酸氨基酸分析和磷酸肽图谱分析表明,磷酸化发生在一个丝氨酸残基上,具体是位于EGP-1胞质结构域的丝氨酸303。用佛波酯处理ME180细胞可增加EGP-1的磷酸化。EGP-1的生物学功能仍有待阐明。在本报告中,我们阐明了蛋白激酶C参与EGP-1的磷酸化,这可能表明该抗原在跨细胞膜信号转导中发挥作用。

相似文献

1
The epithelial/carcinoma antigen EGP-1, recognized by monoclonal antibody RS7-3G11, is phosphorylated on serine 303.上皮/癌抗原EGP-1,可被单克隆抗体RS7-3G11识别,其丝氨酸303位点发生磷酸化。
Int J Cancer. 1995 Aug 9;62(4):472-9. doi: 10.1002/ijc.2910620419.
2
Specificity and properties of MAb RS7-3G11 and the antigen defined by this pancarcinoma monoclonal antibody.单克隆抗体RS7-3G11的特异性和特性以及由这种泛癌单克隆抗体所定义的抗原
Int J Cancer. 1993 Dec 2;55(6):938-46. doi: 10.1002/ijc.2910550611.
3
Characterization of cluster 13: the epithelial/carcinoma antigen recognized by MAb RS7.13号簇的特征:单克隆抗体RS7识别的上皮/癌抗原
Int J Cancer Suppl. 1994;8:98-102. doi: 10.1002/ijc.2910570721.
4
Epitope mapping of SCLC-cluster-2 MAbs and generation of antibodies directed against new EGP-2 epitopes.
Int J Cancer Suppl. 1994;8:64-9. doi: 10.1002/ijc.2910570714.
5
Detection of a putative 30-kDa ligand of the cluster-2 antigen.簇-2抗原假定的30 kDa配体的检测
Int J Cancer Suppl. 1994;8:70-5. doi: 10.1002/ijc.2910570715.
6
Phosphorylated sites of M(r) 25,000 protein, a putative protein phosphatase 2A modulator, and phosphorylation of the synthetic peptide containing these sites by protein kinase C.分子量为25,000的蛋白质(一种假定的蛋白磷酸酶2A调节剂)的磷酸化位点,以及蛋白激酶C对含有这些位点的合成肽的磷酸化作用。
J Biochem. 1996 Apr;119(4):626-32. doi: 10.1093/oxfordjournals.jbchem.a021288.
7
Murine p53 is phosphorylated within the PAb421 epitope by protein kinase C in vitro, but not in vivo, even after stimulation with the phorbol ester o-tetradecanoylphorbol 13-acetate.在体外,小鼠p53可被蛋白激酶C在PAb421表位内磷酸化,但在体内即使在用佛波酯十四烷酰佛波醇乙酯刺激后也不会发生磷酸化。
Oncogene. 1996 Jul 4;13(1):205-11.
8
CD66 monoclonal antibodies recognize a phosphotyrosine-containing protein bearing a carcinoembryonic antigen cross-reacting antigen on the surface of human neutrophils.CD66单克隆抗体识别一种含磷酸酪氨酸的蛋白,该蛋白在人中性粒细胞表面带有癌胚抗原交叉反应抗原。
J Immunol. 1992 Feb 1;148(3):852-60.
9
Phosphorylation of connexin 32, a hepatocyte gap-junction protein, by cAMP-dependent protein kinase, protein kinase C and Ca2+/calmodulin-dependent protein kinase II.环磷酸腺苷依赖性蛋白激酶、蛋白激酶C以及钙离子/钙调蛋白依赖性蛋白激酶II对肝细胞间隙连接蛋白连接蛋白32的磷酸化作用。
Eur J Biochem. 1990 Sep 11;192(2):263-73. doi: 10.1111/j.1432-1033.1990.tb19223.x.
10
Human parainfluenza virus type 3 phosphoprotein: identification of serine 333 as the major site for PKC zeta phosphorylation.人副流感病毒3型磷蛋白:确定丝氨酸333是蛋白激酶Cζ磷酸化的主要位点。
Virology. 1995 Aug 20;211(2):561-7. doi: 10.1006/viro.1995.1438.

引用本文的文献

1
Preclinical Activity of Datopotamab Deruxtecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2, in Uterine Serous Carcinoma.靶向滋养层细胞表面抗原2的抗体药物偶联物达波妥单抗德鲁替康在子宫浆液性癌中的临床前活性
Cancer Res Commun. 2025 May 1;5(5):774-782. doi: 10.1158/2767-9764.CRC-25-0057.
2
Targeting Refractory Triple-Negative Breast Cancer with Sacituzumab Govitecan: A New Era in Precision Medicine.用戈沙妥珠单抗靶向难治性三阴性乳腺癌:精准医学的新时代。
Cells. 2024 Dec 22;13(24):2126. doi: 10.3390/cells13242126.
3
Current Status and Future Prospects of TROP-2 ADCs in Lung Cancer Treatment.
TROP-2 ADC 药物在肺癌治疗中的现状和未来前景。
Drug Des Devel Ther. 2024 Nov 6;18:5005-5021. doi: 10.2147/DDDT.S489234. eCollection 2024.
4
Novel Anti-Trop2 Nanobodies Disrupt Receptor Dimerization and Inhibit Tumor Cell Growth.新型抗Trop2纳米抗体破坏受体二聚化并抑制肿瘤细胞生长。
Pharmaceutics. 2024 Sep 27;16(10):1255. doi: 10.3390/pharmaceutics16101255.
5
The Relationship between Trop-2, Chemotherapeutic Drugs, and Chemoresistance.Trop-2 与化疗药物及化疗耐药性的关系。
Int J Mol Sci. 2023 Dec 20;25(1):87. doi: 10.3390/ijms25010087.
6
Therapeutic Targets of Monoclonal Antibodies Used in the Treatment of Cancer: Current and Emerging.用于癌症治疗的单克隆抗体的治疗靶点:现状与新进展
Biomedicines. 2023 Jul 24;11(7):2086. doi: 10.3390/biomedicines11072086.
7
Overview of Trop-2 in Cancer: From Pre-Clinical Studies to Future Directions in Clinical Settings.癌症中Trop-2概述:从临床前研究到临床环境中的未来方向
Cancers (Basel). 2023 Mar 13;15(6):1744. doi: 10.3390/cancers15061744.
8
Trop-2 and Nectin-4 immunohistochemical expression in metastatic colorectal cancer: searching for the right population for drugs' development.Trop-2 和 Nectin-4 在转移性结直肠癌中的免疫组化表达:为药物研发寻找合适的人群。
Br J Cancer. 2023 Mar;128(7):1391-1399. doi: 10.1038/s41416-023-02180-7. Epub 2023 Feb 9.
9
A review of recent advances on single use of antibody-drug conjugates or combination with tumor immunology therapy for gynecologic cancer.抗体药物偶联物单用或与肿瘤免疫疗法联合用于妇科癌症的近期进展综述。
Front Pharmacol. 2022 Dec 22;13:1093666. doi: 10.3389/fphar.2022.1093666. eCollection 2022.
10
TROP2 Represents a Negative Prognostic Factor in Colorectal Adenocarcinoma and Its Expression Is Associated with Features of Epithelial-Mesenchymal Transition and Invasiveness.TROP2是结直肠癌的一个负性预后因素,其表达与上皮-间质转化及侵袭特征相关。
Cancers (Basel). 2022 Aug 26;14(17):4137. doi: 10.3390/cancers14174137.